(Q44573481)

4 December 2017

title

Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece (English)

1 reference

4 December 2017

1 reference

1 reference

5

1 reference

4 December 2017

Nikos Maniadakis

1

1 reference

4 December 2017

Mattias Ekman

series ordinal

2

1 reference

4 December 2017

Vasilios Fragoulakis

series ordinal

3

1 reference

4 December 2017

Vasiliki Papagiannopoulou

series ordinal

4

1 reference

4 December 2017

language of work or name

1 reference

22 April 2010

1 reference

The European Journal of Health Economics

4 December 2017

published in

1 reference

4 December 2017

volume

12

1 reference

4 December 2017

issue

3

1 reference

4 December 2017

page(s)

253-261

1 reference

Epidemiology and prevention of hypertension

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

Selected major risk factors and global and regional burden of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

Global burden of hypertension: analysis of worldwide data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

Cost-effectiveness of losartan versus atenolol in treating hypertension--an analysis of the LIFE study from a Swiss perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

Effects of Losartan-based therapy on the incidence of end-stage renal disease and associated costs in type 2 diabetes mellitus: A retrospective cost-effectiveness analysis in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

Prevalence of nonfatal coronary heart disease among American adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

Incidence and epidemiology of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

Stroke incidence and prevalence in Europe: a review of available data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

Prevalence, awareness, treatment and control of hypertension in a general population sample of 26,913 adults in the Greek EPIC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

Swedish population health-related quality of life results using the EQ-5D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

A meta-analysis of quality-of-life estimates for stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

Lifetime Risk for Developing Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10198-010-0243-5

Prevalence, awareness, treatment and control of hypertension in Hellas, Greece: the Hypertension Study in General Practice in Hellas (HYPERTENSHELL) national study

21 January 2018

1 reference

12 December 2020

Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension

1 reference

12 December 2020

Cost analysis of different pharmacological treatment strategies in elderly hypertensives

1 reference

12 December 2020

Epidemiology of heart failure

1 reference

12 December 2020

Establishing health state valuations for disease specific states: an example from heart disease

1 reference

12 December 2020

Medical care expenditures for hypertension, its complications, and its comorbidities

1 reference

12 December 2020

Development of predictive models for long-term cardiovascular risk associated with systolic and diastolic blood pressure

1 reference

12 December 2020

An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands

1 reference

12 December 2020

Epidemiology of heart failure in Sweden--a national survey

1 reference

12 December 2020

A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy

1 reference

12 December 2020

2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

1 reference

12 December 2020

Incremental expenditure of treating hypertension in the United States.

1 reference

12 December 2020

Statistical modelling of 10-year fatal cardiovascular disease risk in Greece: the HellenicSCORE (a calibration of the ESC SCORE project).

1 reference

12 December 2020

Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis

1 reference

12 December 2020

10.1007/S10198-010-0243-5

Identifiers

DOI

1 reference

4 December 2017

1 reference